Citizens Reiterates Market Outperform on Structure Therapeutics, Maintains $110 Price Target
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsReiterationPrice Target
Citizens analyst Jonathan Wolleben reiterates Structure Therapeutics (NASDAQ:GPCR) with a Market Outperform and maintains $110 price target.
Citizens analyst Jonathan Wolleben reiterates Structure Therapeutics (NASDAQ:GPCR) with a Market Outperform and maintains $110 price target.